 |
|
 |
- November 20, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"The Role of Fibrates in Reducing Cardiovascular Risk"Prof. Philip Barter (biography)
English - 2005-09-11 - 24 minutes
|
 | (43 slides) |
Summary :
In this presentation Prof. Barter reviews data showing how certain types of individuals receive enhanced benefit from fibrate treatment, in terms of reduced cardiovascular risk.
Fibrates activate the nuclear receptor PPAR-alpha, and have several possible anti-atherogenic mechanisms. Prof. Barter presents data from the Helsinki Heart Study (HHS)and the VA-HIT Study both using gemfibrozil, in primary and secondary prevention respectively. These data show how increased body weight, low HDL cholesterol, elevated plasma triglyceride, elevated fasting plasma insulin and type 2 diabetes affect the magnitude of reduction in CHD events due to gemfibrozil treatment (1-3).
Unlike in the HHS and VA-HIT studies, treatment with bezafibrate in the BIP study (secondary prevention) did not result in a significant reduction in CHD events in the active treatment group, although those with elevated triglycerides did have a significant reduction in events (4). In those with the metabolic syndrome, non-fatal myocardial infarction and any myocardial infarction were also significantly reduced (5).
Finally, results from the FIELD Study (Fenofibrate Intervention and Event Lowering in Diabetes) comparing the effects of micronized fenofibrate versus placebo (minimum 5 years treatment) on total CHD and total stroke, are to be presented at the 2005 AHA meeting in Dallas.
Copyright © 2005 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Data from the HHS and VA-HIT studies
- Data from the BIP Study
- Introduction to the FIELD Study
Bibliographic references :
1. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH.Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992 Jan;85(1):37-45.
2. Leena Tenkanen, PhD; Matti Mänttäri, MD; Vesa Manninen, MD. Some Coronary Risk Factors Related to the Insulin Resistance Syndrome and Treatment With Gemfibrozil: Experience From the Helsinki Heart Study Circulation. 1995;92:1779-1785.
3. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW.Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).Arch Intern Med. 2002 Dec 9-23;162(22):2597-604.
4. BIP Study Group. Circulation.2000.
5. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005 May 23;165(10):1154-60.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
